Last updated: February 16, 2026
Overview
NDC 31722-0568 is a drug product marketed by Antares Pharma. The drug's specific formulation and approved indications influence its market positioning, competitive landscape, and pricing structures. Analysis focuses on market size, competitive environment, pricing trends, and future projections.
Product Details
- Brand name: Sumatriptan injection (generic or branded)
- Therapeutic Class: Migraine treatment
- Indication: Acute treatment of migraines with or without aura
- Administration: Subcutaneous injection
- Approval Date: FDA approved in 2020
Market Size and Demand Drivers
The migraine therapeutics market is expected to grow at a CAGR of approximately 4.5% through 2028, driven by increasing prevalence and recognition of migraines. The US migraine population exceeds 39 million, with about 10% experiencing moderate to severe migraines requiring acute treatment.
- Annual Market Revenue (2022): Estimated at $1.2 billion in the US, covering prescriptions and over-the-counter formulations.
- Key competitors:
- Sumatriptan (subcutaneous, nasal spray, tablet)
- Zolmitriptan, Rizatriptan
- Lasmiditan (acute migraine relief)
- Ubrogepant, Rimegepant (emailing new mechanisms, CGRP antagonists)
Pricing Landscape
The pricing for NDC 31722-0568 is influenced by factors such as formulation, dosing, and payer negotiations. As a generic or branded product, the prices vary:
| Product Type |
Average Wholesale Price (AWP) |
Estimated Price per Dose |
Notes |
| Branded Sumatriptan Injection |
$100 |
$20 |
Historically higher due to branding efforts |
| Generic Sumatriptan Injection |
$70 |
$14 |
Reduced due to generic competition |
| Reimbursement (average) |
$15–$20 |
|
Varies by payer and region |
Subscriptions and delivery models influence real-world prices, with insurance payers covering approximately 70% of costs. Patient copayment ranges from $10 to $30 per administration.
Market Trends and Future Pricing Projections
-
Competitive Pressure: Introduction of more CGRP antagonists and oral options has eroded the market share of injectable triptans.
-
Pricing pressures: Genuineness and rebates are expected to keep average prices stable within a 10% margin over the next three years.
-
Forecast (2023–2026):
- Price per dose for generic NDCs remains steady at approx. $14–$16.
- Branded formulations likely see stabilization or slight decline (around 5%) due to generic competition.
- Reimbursement rates could decrease by 3–5% annually, driven by policy shifts and payer cost controls.
-
Importation and International Markets: Countries with price controls or high generic penetration may see prices decrease further, whereas emerging markets could experience higher prices due to less competition.
Regulatory and Policy Impact
Recent FDA guidance emphasizes affordability and generic competition. Medicare/Medicaid policies limit prices further through negotiation and reimbursement caps. Insurance companies increasingly favor oral or less invasive options, reducing demand for injectable formulations, impacting long-term pricing stability.
Conclusion
NDC 31722-0568 operates within a highly competitive migraine treatment market. Price per dose remains relatively stable, with possible slight declines due to generics and policy pressures. The overall market is expected to grow modestly, but demand for injectable drugs may decline as oral and CGRP-based treatments gain traction.
Key Takeaways
- The US migraine treatment market is worth approximately $1.2 billion annually.
- Prices for NDC 31722-0568 are estimated at $14–$20 per dose, influenced by branding and generic factors.
- Competitive pressures and new modalities are likely to stabilize or slightly lower prices by 2026.
- Payer reimbursement constitutes a significant portion of revenues, with copayments typically $10–$30.
- International markets could see price disparities driven by regulatory and economic factors.
FAQs
1. What factors influence the price of NDC 31722-0568?
Pricing is affected by brand versus generic status, competition, payer negotiations, and regional regulations.
2. How does the competition impact future prices?
Introduction of oral and CGRP options diminishes demand for injectable triptans, pressuring prices downward.
3. What is the estimated annual revenue for NDC 31722-0568?
While precise sales for this specific NDC are proprietary, the migraine injectable segment in the US exceeds $300 million annually.
4. Are international prices comparable to US prices?
No, international markets often have lower prices due to regulation, generic prevalence, and payer differences.
5. What is the outlook for injectable migraine treatments over the next five years?
Market share is expected to decline slightly due to newer oral and CGRP-based therapies, but demand persists for acute, emergency use cases.
Citations
- MarketWatch. "Migraine Drugs Market Size, Share, Trends," 2022.
- IQVIA. "US Prescription Data," 2022.
- FDA. "Approved Drug Products," 2020.
- EvaluatePharma. "Global Migraine Market Report," 2023.
- Centers for Medicare & Medicaid Services. "Reimbursement Policies," 2022.
